W3L1 Mon menopause Flashcards

1
Q

What is menopause

A
  • The menopause is the final menstrual period
  • Average age of menopause around 51-52 years (age range 48-55 years)
  • Defined retrospectively after 12 months of absent periods
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Stages of manopause

A

Peri-menopause, menopause transition, Climacteric
* The period when ovarian function declines, cycles are irregular and menopausal symptoms appear
* Begins mid to late 40s, ends one year after menopause
Post menopause
* The whole lifetime after menopause
* No periods, no ovulations, steroid hormones low, cannot conceive
Early menopause
* 40-45 years, 5-8% of women
Premature ovarian insufficiency (POI), premature menopause
* Menopause prior to 40 years old, 2% of women (Mishra et al., 2017 Human Reprod)
* May have intermittent ovarian activity, pregnancy rate 5-50% in lifetime

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Changes in age of menopause

A

-Increased life expectancy from ~42 to ~85 in 100 yrs, with 95% women now reaching menopause
* Factors regulating the age at natural menopause are poorly understood/controversial
* Genetic factors – are important
* Cigarette smoking - Menopause is 1-2 yrs earlier
* Surgical history - Hysterectomy may reduce the age at menopause by around 3-4 yrs
* Ethnicity
* High BMI
* Age at Menarche (<12yrs old)?
* Nulliparity
* Not influenced by Oral contraceptive pill

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Age related decline in ovarian follicle numbers

A

Term 1-2 million follicles
Puberty 300 000-400 000
37 years 100 000, then rapid loss
Peri-menopausal threshold <1000 follicles?
Also decline in quality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Peri-menopause Aetiology

A

Ovarian primordial follicles decrease with age with an accelerated rate of loss from 37 years
* Follicles become progressively more resistant to stimulation by gonadotrophins
* Follicles that do develop may not secrete sufficient oestradiol (E2) and progesterone (P4) to produce regular menstruation- erratic/short cycle (follicular phase)
* Decrease in oestrogen (and progesterone), follicular –ve feedback reduced – multiple ovulation – twinning risk
* Irregular anovulatory cycles lead to prolonged unopposed oestrogen
* May lead to endometrial hyperplasia and cancer risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Peri-menopause endocrine changes

A
  • Decreased ovarian inhibin B, AMH from the ovarian granulosa cells
  • Gradual rise in FSH
  • Fluctuations in oestradiol and progesterone
  • No substantial changes in androgen levels
  • Sex steroid levels fluctuate markedly on a daily basis
  • Measuring sex steroids is not useful when a woman of normal menopausal age develops symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Menopause characteristics

A
  • Decline in oocyte quantity and quality in the years preceding
  • Loss of ovarian follicular activity at menopause
  • Very low oestrogen (and progesterone)
  • Increased FSH/LH levels
  • Cessation of menstruation
  • Cessation/reduction of sexual drive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Menopause ovarian and endocrine changes

A
  • Ovarian primordial follicle stores are exhausted by atresia and ovulation
  • Ovulation will not occur after menopause, but this is retrospective
  • Therefore use contraception until no periods for one year, as ovulation may occur right up until last period, though less frequently
  • Oestradiol declines following menopause- lack of negative feedback
    FSH >40 u/l
    LH >30-40 u/l
  • Androstenedione is still produced by the ovary and adrenal gland and is converted in peripheral tissues to oestrone (E1) = low levels
  • Androgens gradually decline during reproductive life but no dramatic change after menopause
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Aetiology of Premature Menopause/ Premature Ovarian Insufficiency (POI) <40yrs

A

Idiopathic (> 70% of cases) Spontaneous POI
Rare causes: Galactosaemia
Auto-immune Addison’s disease, thyroid abnormalities
Genetic: Turner’s syndrome, Fragile X syndrome
Iatrogenic: Surgery/chemo/radiotherapy (8-19% of women under 40)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Premature Menopause/
Premature Ovarian Insufficiency (POI) Diagnosis

A
  • No periods for 4 months before age 40
  • FSH levels greater than 40mIU/ml on 2 occasions at least 1 month apart (never rely on one of level); day 2-6 if cycling
  • Exclusion of all other causes of absent periods, chromosome test
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Management of POI

A
  • NO CURE
  • Actually still need contraception: lifetime chance of ever conceiving 5-10%
  • HRT/contraception until around 50 years- because ↑ mortality due to osteoporosis and cardiovascular issues
  • For young women/girls- monitoring key is susceptible
  • If chemo/surgical – move ovary out of the way (experimental)
  • Ovarian cryopreservation
  • Superovulation- egg freezing or IVF
  • Egg Donation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Oestrogen-related consequences of Menopause incidence

A

20-40% of women have menopausal symptoms requiring treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Oestrogen-related consequences of Menopause short-term problem

A
  • vasomotor symptoms (hot flushes, night sweats, formication- skin thin and dry)
  • urogenital symptoms (vaginal dryness, atrophic vaginitis, dyspareunia, dysuria, frequency)
  • sleep disturbance
  • reduced libido
  • depression, anxiety, labile mood
  • memory loss, fatigue (may be due to other not sleeping etc)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Oestrogen-related consequences of Menopause medium and long-term problem

A
  • Bone loss and osteoporosis
  • Weight gain - change in body form (pear to apple), ↓sensitivity of tissues to insulin (hyperglycaemia)
  • Cardiovascular disease – increase blood cholesterol, renin (angiotensin II) linked to hypertension
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Hot Flushes: oestrogen related consequences

A
  • Most common symptom- occurs in ~ 80% of women
  • Mechanisms not known- hypothalamus thermoregulation
  • Last 4 min on average (1 to > 10 times a day)
  • Up to 30-50% resolve after 3 to 12mths
  • Up to 40% may continue to have significant symptoms up to 10 years after menopause
  • Increased with smoking, alcohol, surgical menopause, caffeine, weight
  • Main reason why women request treatment
  • Oestrogen: most effective treatment, 80% reduction
  • Meditation, relaxation to reduce anxiety
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Urogenital symptoms

A
  • Start at late peri-menopasuse
  • Affects ~ 40% of post menopausal women
  • Persist or worsen over time- atrophy of E2 sensitive tissues
  • Vaginal dryness, discomfort, pruritis, dyspareunia, UTI (change to alkaine pH) and urgency- epithelium thinning
  • Pallor dryness, redness, decreased rugosity
  • Endometrial atrophy- thin, exposed vessels- can cause bleeding
  • First line is intra-vaginal oestrogen (not systemic HRT)
  • For most patients
17
Q

Other symptoms of oestrogen related consequences of menopause

A
  • Musculoskeletal aches and pain
  • Skin thinning, dryness and itchiness (formication)
  • Hair thinning and loss, male pattern baldness in some women- due to androgen:E2 ratio
  • Facial hair growth
  • CNS, decrease memory – especially after surgical induced menopause, slower cognitive function
18
Q

Menopause: emotional health

A
  • Psychological symptoms affect 25-50% of women
  • No direct evidence for increased depression
  • Decreased serotonin levels
19
Q

Bones and Osteoporosis

A
  • Oestrogen deficiency increases bone reabsorption- osteoclast activity
  • Directly impairs gut calcium absorption
  • Directly increases renal calcium excretion
  • Sharp acceleration of bone loss during the initial 5 years following menopause (35%/year)
  • Rate of loss then falls back to the age related loss of 1%/year –ethnicity a factor
  • Low bone mass increases fracture risk- ↑ mortality
  • Prevalence 4% around 50-59 yrs old, >50 % by 80 yrs old
  • Early PREVENTION is key!!
  • Calcium intake (diet- 1200mg/day), Vitamin D (800-1000U/day)
  • Weight-bearing exercise
  • Good nutrition – avoid toxins alcohol, caffeine, smoking
  • HRT- only helpful before 60 yrs old – prevent fractures, can’t reverse damage
20
Q

Body weight, shape and lipid metabolism

A
  • As age increase natural tendency for weight gain
  • Decrease lean mass, increase body and trunk fat
  • Absence of oestrogen at menopause:
  • increased lipoprotein lipase enzyme:
  • increased cholesterol and LDL and decreased HDL
  • plus lower lipolysis in gluteal and abdominal regions:
  • slower fat metabolism
  • body shape changes from female ‘pear’ to male ‘apple’ pattern
21
Q

Cardiovascular risk

A

Major killer of women- contributes to ~50% of deaths
* Lack of E2- increases risk of coronary heart disease (CHD) similar to men
* After menopause, increasing central adiposity, decreased resting energy expenditure, worsening CVS, lipid and metabolic profiles
* Hypertension (HT)- Lack of oestrogen affects on the renin angiotensin system
* Potentially mediated by low oestrogens and loss of inhibition of metabolic neuropeptides
* Together with insulin-resistance (diabetic women) further increases the CHD risk post menopausal
* HRT does not prevent Cardiovascular Disease (CVD), may exacerbate in some women

22
Q

Menopause: Management and treatment
Hormone Replacement Therapy

A
  • Safe and effective if used in peri-menopausal or early postmenopausal women (≤ 5 years of menopause) with vasomotor symptoms
  • If given using these guidelines- no contraindications (breast/endometrial cancer/cardiovascular issues), if so case by case
  • HRT contains oestrogen to treat symptoms and progestin (if needed) to protect the endometrium
23
Q

Risk of HRT

A
  • Combined oestrogen and progestin, given to post menopausal women 50-79 years
  • Increased risk of stroke (0.8/1000/year)
  • Increased risk of clots (0.8/1000/year)
  • Increased risk of breast cancer with >5 years use (0.8/1000/year)
  • Increased incidence of coronary heart disease
  • BUT new data from 2017 (Manson et al., JAMA) - follow up of these cohorts (27,000 women, found NO change in mortality rates between women who did or didn’t take HRT.
    However, for women who did take a E2 and P4 combined treatment, the risk of breast cancer was still elevated.
  • Also new data 2019 (Lancet article)- meta-analysis using 108,647 postmenopausal women showed HRT > 1 yr after 50 yrs old lead to ↑ breast cancer by the age of 65 yrs old, worst is the combined E2 and P4 HRT.
  • Very different to treating POI, in which women are expecting to see E2 and P4 at that age (before 51 years old)
24
Q

Benefits of HRT

A
  • Most effective treatment for menopausal symptoms
  • Reduces frequency and severity vasomotor symptoms by 75-85%
  • Improves vaginal dryness and vaginal/endometrial atrophy
  • Maintains bone density and reduces fracture risk (1/1000 women/year), but not first line for treatment for bone
  • May improve QOL, sleep, muscle aches and pains
  • Lowers incidence of Alzheimer’s disease
  • Reduced colorectal cancer risk 0.8/1000/year (combined long term)
25
Q

Clinical practice guidelines (ACEC, FDA)

A
  • Maybe a time of significant physiological, emotional and physical change during mid-life
  • Lifestyle advice remains the main focus for the mid-life woman. Important to understand these changes so we may best address the needs of women
  • Limited efficacy/safety data on complementary medicines
  • HRT indicated only for moderate to severe menopausal symptoms (flushes, urogenital), women should consider the risks and benefits
  • Use HRT at the lowest dose and for the shortest duration possible, in peri-menopausal or early post menopausal women not >60 years
  • Healthy women with no contraindications
  • Do not use HRT for the prevention of CVD or dementia. HRT is not a first line treatment for osteoporosis